Impact of intravitreal triamcinolone acetonide versus intravitreal bevacizumab on retrobulbar hemodynamic in patients with diabetic macular edema

References

• Massin P, Audren F, Hauchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 2004;111:218–224
   PubMed Web of Science ®Google Scholar
• Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109:920–927
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581–611
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–2342
   PubMed Web of Science ®Google Scholar
• Mason JO, Nixon PA, White MF. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2006;142:685–688
   PubMed Web of Science ®Google Scholar
• Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006;26:999–1005
   PubMed Web of Science ®Google Scholar
• Mawatari Y, Koga T, Inumaru J, et al. The effect of subtenon triamcinolone acetonide injection for diabetic macular edema on retinal and choroidal circulation. Am J Ophthalmol 2005;140:948–949
   PubMed Web of Science ®Google Scholar
• Cekic O, Bardak Y, Tig S, et al. Hemodynamic response to intravitreal triamcinolone in eyes with macular edema: intravitreal triamcinolone and ocular blood flow. Int Ophthamol 2007;27:313–319
   PubMedGoogle Scholar
• Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 2001;280:1375–1386
   PubMed Web of Science ®Google Scholar
• Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99:1232–1239
   PubMed Web of Science ®Google Scholar
• Lun H, Kung-Hung L, Yuan-Chieh L, et al. Acute vision loss after intravitreal injection of bevacizumab (Avastin) associated with ocular ischemic syndrome. Ophthalmologica 2010;224:86–89
   PubMed Web of Science ®Google Scholar
• Titon RG, Chang KC, Leleune WS, et al. Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF. Invest Ophthalmol Vis Sci 1999;40:689–696
   PubMed Web of Science ®Google Scholar
• Uhlmann S, Friedrichs U, Eichler W, et al. Direct measurements of VEGF-induced nitric oxide production by choroidal endothelial cells. Microvasc Res 2001;62:179–189
   PubMed Web of Science ®Google Scholar
• Sacu S, Pemp B, Weigert G, et al. Response of retinal vessels and retrobulbar hemodynamics to intravitreal anti-VEGF treatment in eyes with branch retinal vein occlusion. Invest Ophthalmol Vis Sci 2011;52:3046–3050
   PubMed Web of Science ®Google Scholar
• Guven D, Ozdemir H, Hassanreisoglu B. Hemodynamics alterations in diabetic retinopathy. Ophthalmology 1996;103:1245–1249
   PubMed Web of Science ®Google Scholar
• Williamson TH, Harris A. Color Doppler ultrasound imaging of the eye and orbit. Surv Ophthalmol 1996;40:255–267
   PubMed Web of Science ®Google Scholar
• Mokbel TH, Shahin MM, El-Said EM, et al. Potential diagnostic value of fluorescein angiography and color Doppler imaging in primary open angle glaucoma. Eur J Ophthalmol 2009;19:957–962
   PubMed Web of Science ®Google Scholar
• Matthiessen Ety, Zeitz O, Richard G, et al. Reproducibility of blood flow velocity measurements using decoded Doppler imaging. Eye 2004;18:400–405
   PubMed Web of Science ®Google Scholar
• Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs – an extension of the modified Airlie House classification. ETDRS report number 10. Early treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98:786–806
   PubMed Web of Science ®Google Scholar
• Toklu Y, Cakmak HB, Raza S, et al. Short-term effects of intravitreal bevacizumab (Avastin) on retrobulbar hemodynamiocs in patients with neovascular age-related macular degeneration. Acta Ophthalmol 2011;89:41–45
   PubMedGoogle Scholar
• Fung AE, Rosenfeld PJ, Reichel E. The International Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344–1349
   PubMed Web of Science ®Google Scholar
• Wu L, Martinez-Castellanos MA, Quirroz-Mecado H, et al. Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injection of bevacizumab (Avastin): results of the pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246:81–87
   PubMed Web of Science ®Google Scholar
• Taylor GA, Short BL, Walker LK, et al. Intracranial blood flow: quantification with duplex Doppler and colour Doppler flow US. Radiology 1990;176:231–236
   PubMed Web of Science ®Google Scholar
• Burgansky-Eliash Z, Barak A, Barash H, et al. Increased retinal blood flow velocity in patients with early diabetes mellitus. Retina 2012;32:112–119
   PubMed Web of Science ®Google Scholar